Lidocaine and Monoethylglycinexylidide Serum Determinations to Analyze Liver Function of Cirrhotic Patients After Oral Administration

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 1999 Apr 29

PMID 10219840

Citations 4

Authors

A E Munoz

C Miguez

M Rubio

M Bartellini

D Levi

A Podesta

V Niselman

R Terg

Affiliations

Soon will be listed here.

Abstract

Our aim was to compare standard liver function tests (serum bilirubin, serum albumin and prothrombin concentration), with lidocaine and monoethylglycinexylidide pharmacokinetic parameters, after oral lidocaine administration, to assess hepatic function of cirrhotic individuals. Twenty-one consecutive cirrhotic patients, nine consecutive acute hepatitis patients, and nine healthy individuals received oral lidocaine. Lidocaine and monoethylglycinexylidide serum concentrations were determined by the TDx system. Cirrhotic patients had higher lidocaine and lower monoethylglycinexylidide serum concentrations and differences in its pharmacokinetic variables, compared to control and hepatitis groups (P < 0.05). Sensitivity of lidocaine serum determinations (100%) was greater than sensitivity of serum bilirubin (57%), serum albumin (62%), and prothrombin concentrations (43%) and monoethylglycinexylidide serum concentrations (57%) in differentiating cirrhotic individuals from controls. In conclusion, after oral administration, lidocaine and monoethylglycinexylidide pharmacokinetic parameters are significantly altered in cirrhotic patients compared to normal and acute hepatitis subjects. Lidocaine pharmacokinetic parameters would be better than those of monoethylglycinexylidide and standard liver function tests in the evaluation of liver function of cirrhotic patients.

Citing Articles

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver.

Jovanovic M, Kovacevic M, Vezmar-Kovacevic S, Palibrk I, Bjelanovic J, Miljkovic B J Med Biochem. 2023; 42(2):304-310.

PMID: 36987422 PMC: 10040201. DOI: 10.5937/jomb0-38952.

Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts.

Devriendt N, Serrano G, Croubels S, Stock E, Vandermeulen E, Paepe D J Vet Intern Med. 2021; 35(1):261-268.

PMID: 33432666 PMC: 7848304. DOI: 10.1111/jvim.16030.

Even 'safe' medications need to be administered with care.

Lutwak N, Howland M, Gambetta R, Dill C BMJ Case Rep. 2013; 2013.

PMID: 23283606 PMC: 3604254. DOI: 10.1136/bcr-2012-006204.

Oral or intravenous lidocaine administration to perform megx test?.

Giannini E, Botta F, Romagnoli P, Testa R Dig Dis Sci. 2000; 45(5):1011-2.

PMID: 10795769 DOI: 10.1023/a:1005549813970.

References

Meyer B, Luo H, Bargetzi M, Renner E, Stalder G . Quantitation of intrinsic drug-metabolizing capacity in human liver biopsy specimens: support for the intact-hepatocyte theory. Hepatology. 1991; 13(3):475-81. View

Burdelski M, Oellerich M, Lamesch P, Raude E, Ringe B, Neuhaus P . Evaluation of quantitative liver function tests in liver donors. Transplant Proc. 1987; 19(5):3838-9. View

Huet P, Pomier-Layrargues G, Villeneuve J, Varin F, VIALLET A . Intrahepatic circulation in liver disease. Semin Liver Dis. 1986; 6(4):277-86. DOI: 10.1055/s-2008-1040610. View

Tygstrup N . Assessment of liver function: principles and practice. J Gastroenterol Hepatol. 1990; 5(4):468-82. DOI: 10.1111/j.1440-1746.1990.tb01426.x. View

Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrini G . Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clin Pharmacol Ther. 1988; 44(6):642-9. DOI: 10.1038/clpt.1988.206. View

Kolars J, Schmiedlin-Ren P, Schuetz J, Fang C, Watkins P . Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992; 90(5):1871-8. PMC: 443248. DOI: 10.1172/JCI116064. View

Arrigoni A, Gindro T, Aimo G, Cappello N, Meloni A, Benedetti P . Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology. 1994; 20(2):383-7. View

Schroeder T, Gremse D, Mansour M, Theuerling A, Brunson M, Ryckman F . Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients. Transplant Proc. 1989; 21(1 Pt 2):2299-301. View

Parkinson P, Margolin L, DICKSON D . Oral lignocaine: its absorption and effectiveness in ventricular arrhythmia control. Br Med J. 1970; 2(5700):29-30. PMC: 1699788. DOI: 10.1136/bmj.2.5700.29. View

10.

Meyer-Wyss B, Renner E, Luo H, Scholer A . Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol. 1993; 19(1):133-9. DOI: 10.1016/s0168-8278(05)80186-2. View

11.

Gremse D, Schroeder T, Balistreri W . Assessment of lidocaine metabolite formation as a quantitative liver function test in children. Hepatology. 1990; 12(3 Pt 1):565-9. DOI: 10.1002/hep.1840120319. View

12.

McIntyre N . The limitations of conventional liver function tests. Semin Liver Dis. 1983; 3(4):265-74. DOI: 10.1055/s-2008-1040779. View

13.

Martinez-Hernandez A, Martinez J . The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis. Hepatology. 1991; 14(5):864-74. DOI: 10.1002/hep.1840140519. View

14.

Huang Y, Lee S, Deng J, Wu J, Lu R, Lin Y . Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol. 1993; 19(1):140-7. DOI: 10.1016/s0168-8278(05)80187-4. View

15.

Sawchenko P, Friedman M . Sensory functions of the liver--a review. Am J Physiol. 1979; 236(1):R5-20. DOI: 10.1152/ajpregu.1979.236.1.R5. View

16.

Oellerich M, Burdelski M, Lautz H, Binder L, Pichlmayr R . Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology. 1991; 14(6):1029-34. View

17.

BIRCHER J . Quantitative assessment of deranged hepatic function: a missed opportunity?. Semin Liver Dis. 1983; 3(4):275-84. DOI: 10.1055/s-2008-1040780. View

18.

Watkins P . Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis. 1990; 10(4):235-50. DOI: 10.1055/s-2008-1040480. View

19.

Eisinger A, Hellier M . Oral lignocaine. Lancet. 1969; 2(7633):1303. DOI: 10.1016/s0140-6736(69)90841-1. View

20.

Oellerich M, Burdelski M, Lautz H, Schulz M, Schmidt F, Herrmann H . Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit. 1990; 12(3):219-26. DOI: 10.1097/00007691-199005000-00002. View